Proliferative Activity in Pancreatic Endocrine Tumors: Association with Function, Metastases, and Survival

Endocrine Pathology

Volumn 8, Issue 3, 1997, Pages 181-187

  Clarke, Martha R ^a,c   Baker, Evan E ^a   Weyant, Robert J ^b   Hill, Lisa ^a   Carty, Sally E ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b Center for Vaccine Research   (United States)

^c Montefiore Hospital   (United States)

Author keywords

Metastases; MIB 1; Pancreatic endocrine tumor; Prognosis; Proliferation; Survival

Indexed keywords

EID: 0000681353     PISSN: 10463976     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02738784     Document Type: Article

References (26)

1. Larsson L-I. Endocrine pancreatic tumors. Hum Pathol 9:401-416, 1978.
2. Mukai K, Greider MH, Grotting JC, Rosai J. Retrospective study of 77 pancreatic endocrine tumors using the immunoperoxidase method. Am J Surg Pathol 6:387-399, 1982.
3. Heitz PhU, Kloppel G. Endocrine tumors of the pancreas and duodenum. Verh Dtch Ges Pathol 71:202-221, 1987.
4. Kloppel G, Delling G, Knipper A, Heitz PU. Immunocytochemical mapping of pancreatic apudomas in multiple endocrine adenomatosis with primary hyperparathyroidism. Acta Endocrinol 87(Suppl 215):57,58, 1978.
5. Eckhauser FE, Cheung PS, Vinik AI, Strodel WE, Lloyd RV, Thompson NW. Non-functioning malignant neuroendocrine tumors of the pancreas. Surg 100:978-987, 1986.
6. White TJ, Edney JA, Thompson JS, Karrer FW, Moor RJ. Is there a prognostic difference between functional and nonfunctional islet cell tumors? Am J Surg 168:627-630, 1994.
7. Compton CC. Diseases of the pancreas. In Weidner N., ed. The difficult diagnosis in surgical pathology. Philadelphia: Saunders, 1996; 270-272.
8. Solcia E, Capella G, Fiocca R, Cornaggis M, Bosi H. The gastroenteropancreatic endocrine system and related tumors. Gastroentcrol Clin North Am 18:671-693, 1989.
9. Heitz PU, Kasper M, Kloppel G, Polak JM, Vaitukaitis JL. Glycoprotein-hormone alpha-chain production by pancreatic endocrine tumors: a specific marker for malignancy. Cancer 51:277-282, 1983.
10. Heitz, PU, von Herbay G, Kloppel G, Komminoth P, Kasoer M, Hofler H, Muller K-M, Oberholzer M. The expression of subunits of human chorionic gonadotropin (hCG) by nontrophoblastic, nonendocrine, and endocrine tumors. Am J Clin Pathol 88:467-472, 1987.
11. Viale G, Doglioni C, Gamgacorta M, Zamboni G, Coggi G, Bordi C. Progesterone receptor immunoreactivity in pancreatic endocrine tumors. An immunocytochemical study of 156 neuroendocrine tumors of the pancreas, gastrointestinal and respiratory tracts, and skin. Cancer 70:2268-2277, 1992.
12. Hofler H, Ruhri C, Putz B, Wirnsberger G, Hauser H. Oncogene expression in endocrine pancreatic tumors. Virchows Arch B Cell Pathol 55:355-361, 1988.
13. Graeme-Cook F, Bell DA, Flotte I-J, Preffer F, Pastel-Levy C, Nardi G, Compton C. Aneuploidy in pancreatic insulinomas does not predict malignancy. Cancer 66:2365-2368, 1990.
14. Donow C, Baisch H, Heitz PU, Kloppel G. Nuclear DNA content in 27 pancreatic endocrine tumors: correlation with malignancy, survival and expression of glycoprotein hormone alpha chain. Virchows Arch 419:463-468, 1991.
15. Kenny BD, Sloan JM, Hamilton PW, Watt PCH, Johnston CF, Buchanan KD. The role of morphometry in predicting prognosis in pancreatic islet cell tumors. Cancer 64:460-465, 1989.
16. Ruschoff I, Willemer S, Brunzel M, Trautmann MH, Frank M, Arnold R, Kloppel G. Nucleolar organizer regions and glycoprotein-hormone α-chain reaction as markers of malignancy in endocrine tumours of the pancreas. Histopathol 22:51-57, 1993.
17. Pelosi G, Zamboni G, Doglioni C, Rodella S, Bresaola F., Iacono C, Serio G, Iannucci A, Scarpa A. Immunodetection of proliferating cell nuclear antigen assesses the growth fraction and predicts malignant in endocrine tumors of the pancreas. Am J Surg Pathol 16:1215-1225, 1992.
18. Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H. Cell cycle analysis of a cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67. J Immunol 133:1710-1715, 1984.
19. Rose DSC, Maddox PH, Brown DC. Which proliferation markers for routine immunohistology: a comparison of five antibodies. J Clin Pathol 47:1010-1014, 1994.
20. McCormick D, Chong H, Hobbs C, Datta C, Hall PA. Detection of the Ki-67 antigen in fixed and wax-embedded sections with the monoclonal antibody MIB1. Histopathol 22:355-360, 1993.
21. Linden MD, Torres FX, Kubus J, Zarbo RJ. Clinical application of morphologic and immunocytochemical assessments of cell proliferation. Am J Clin Pathol 97(Suppl):S4-S13, 1992.
22. Keshgegian M, Cnaan A. Proliferation markers in breast carcinoma. Am J Clin Pathol 104:42-49, 1995.
23. Pinder SE, Wencyk P, Sibbering DM, Bell JA, Elston CW, Nicholson R, Robertson JFR, Blamey RW, Ellis IO. Assessment of the new proliferation marker MIB1 in breast carci-noma using image analysis: associations with other prognostic factors and survival. Br J Cancer 71:146-149, 1995.
24. Ng IOL, NaJ, Lai ECS, Fan ST, Ng M. Ki-67 antigen expression in hepatocellular carcinoma using monoclonal antibody MIB1. A comparison with proliferating cell nuclear antigen. Am J Clin Pathol 104:313-318, 1995.
25. Goldblum JR, Shannon R, Kaldjian EP, Thiny M, Davenport R, Thompson N, Lloyd RV. Immunohistochemical assessment of proliferative activity in adrenocortical neoplasms. Mod Pathol 6:663-668, 1993.
26. Clarke MR, Weyant RJ, Watson CG, Carty SE. MIB-1, bcl-2, cathepsin B, cathepsin D, FGF, c-met and type IV collagenase in benign and malignant pheochromocytomas. Mod Pathol 9:47A, 1996.